Matches in Wikidata for { <http://www.wikidata.org/entity/Q91513025> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q91513025 description "article scientifique publié en 2019" @default.
- Q91513025 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q91513025 description "im März 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91513025 description "scientific article published on 25 March 2019" @default.
- Q91513025 description "wetenschappelijk artikel" @default.
- Q91513025 description "наукова стаття, опублікована 25 березня 2019" @default.
- Q91513025 name "Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results" @default.
- Q91513025 name "Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results" @default.
- Q91513025 type Item @default.
- Q91513025 label "Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results" @default.
- Q91513025 label "Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results" @default.
- Q91513025 prefLabel "Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results" @default.
- Q91513025 prefLabel "Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results" @default.
- Q91513025 P1433 Q91513025-6937D021-E5B6-465B-B039-17F1292EC970 @default.
- Q91513025 P1476 Q91513025-08290441-5E3C-4E76-98AB-EA0EB42BE006 @default.
- Q91513025 P2093 Q91513025-2EA8BF11-EF74-4DAA-9430-DD3D2A28996A @default.
- Q91513025 P2093 Q91513025-4141C2D6-7248-48A1-BA23-7E9B8012502D @default.
- Q91513025 P2093 Q91513025-4AF34203-D762-425A-A399-A16E90CEB231 @default.
- Q91513025 P2093 Q91513025-504DD18D-678D-468D-9DE2-D90945E61412 @default.
- Q91513025 P2093 Q91513025-59649AD6-C574-4521-8CB5-345E585A2DEE @default.
- Q91513025 P2093 Q91513025-764587B6-B765-4D9E-B295-93B88609ADFD @default.
- Q91513025 P2093 Q91513025-772A0176-9D61-4D4B-BC53-9496BB542488 @default.
- Q91513025 P2093 Q91513025-8EC19168-2D41-497B-8A50-4EAEBBC547AA @default.
- Q91513025 P2093 Q91513025-93DFB6BD-CD03-4EEA-8FEA-1AA42D4035CC @default.
- Q91513025 P2093 Q91513025-9628EB01-ED75-46CE-94AF-4E9298AB175A @default.
- Q91513025 P2093 Q91513025-9D50CED5-27A1-49A2-BC62-D5B6304FB01A @default.
- Q91513025 P2093 Q91513025-A161475A-0A7A-449D-BFEE-B44748EEB916 @default.
- Q91513025 P2093 Q91513025-CB967D8D-BC7F-41B6-816E-A44C239F4576 @default.
- Q91513025 P2093 Q91513025-D8B3F8FD-73C7-4C9A-AAED-79C0CE0420C6 @default.
- Q91513025 P304 Q91513025-647CF1B9-497F-4B47-97B5-9B9CA594F604 @default.
- Q91513025 P31 Q91513025-C00C379B-C563-4BF2-BDB9-5166E5A8DD51 @default.
- Q91513025 P356 Q91513025-644C0336-F6BA-437A-8B20-67D9093D7126 @default.
- Q91513025 P407 Q91513025-7388499D-CB5F-4AA1-B1CD-658654F4F032 @default.
- Q91513025 P478 Q91513025-39D80A8B-DB77-431D-A177-2A2D49E4426F @default.
- Q91513025 P50 Q91513025-B68D897A-8E2C-4F9B-96DB-C6014DD89982 @default.
- Q91513025 P577 Q91513025-DBA5F8EE-B479-473E-A52C-DED8B04D9555 @default.
- Q91513025 P698 Q91513025-28622298-DD56-45CA-897A-E46FDDFCFD39 @default.
- Q91513025 P921 Q91513025-0C1DEFB6-B996-4964-95BC-C64D8A5694EC @default.
- Q91513025 P921 Q91513025-14419187-6EAA-4DB8-B580-AA45EEE6B183 @default.
- Q91513025 P921 Q91513025-894497D5-57C6-420D-8889-EDCB5484D76A @default.
- Q91513025 P356 J.EPLEPSYRES.2019.03.015 @default.
- Q91513025 P698 31022635 @default.
- Q91513025 P1433 Q15746405 @default.
- Q91513025 P1476 "Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results" @default.
- Q91513025 P2093 "Arie Weinstock" @default.
- Q91513025 P2093 "CBD EAP study group" @default.
- Q91513025 P2093 "Daniel Checketts" @default.
- Q91513025 P2093 "E Martina Bebin" @default.
- Q91513025 P2093 "Elizabeth A Thiele" @default.
- Q91513025 P2093 "Eric D Marsh" @default.
- Q91513025 P2093 "Eric Segal" @default.
- Q91513025 P2093 "Ian Miller" @default.
- Q91513025 P2093 "Kathryn Nichol" @default.
- Q91513025 P2093 "Laurie Seltzer" @default.
- Q91513025 P2093 "Linda C Laux" @default.
- Q91513025 P2093 "Michael Chez" @default.
- Q91513025 P2093 "Robert Flamini" @default.
- Q91513025 P2093 "Yong Park" @default.
- Q91513025 P304 "13-20" @default.
- Q91513025 P31 Q13442814 @default.
- Q91513025 P356 "10.1016/J.EPLEPSYRES.2019.03.015" @default.
- Q91513025 P407 Q1860 @default.
- Q91513025 P478 "154" @default.
- Q91513025 P50 Q89585388 @default.
- Q91513025 P577 "2019-03-25T00:00:00Z" @default.
- Q91513025 P698 "31022635" @default.
- Q91513025 P921 Q1255956 @default.
- Q91513025 P921 Q1544884 @default.
- Q91513025 P921 Q407954 @default.